New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
10:45 EDTTEVA, TEVA, HSP, HSP, VRX, VRX, MYL, MYL, ENDP, ENDP, PRGO, PRGO, ACT, ACT, JAZZ, JAZZ, MNK, MNK, SLXP, SLXPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Analyst will discuss his initiation of coverage of Specialty Pharmaceuticals on a conference call on July 23 at 11 am. Tickers to be discussed include TEVA, MNK, JAZZ, ACT, PRGO, ENDP, MYL, VRX, HSP, SLXP.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 >>
September 28, 2015
13:50 EDTVRXCitron Research sets $130 short-term price target on Valeant
After House Democrats asked to subpoena Valeant for documents relating to drug price increases, Citron Research tweeted that it puts a $130 short-term price target on the stock. Reference Link
13:49 EDTVRXValeant puts active after House Democrats seek subpoena
Subscribe for More Information
13:29 EDTVRXValeant sinks after House Democracts seek subpoena, Bloomberg reports
Valeant Pharmaceuticals shares are plunging after House Democrats asked to subpoena the company for documents relating to drug price increases, Bloomberg reports. In midday trading, shares of Valeant are down 13% to $173.75. Reference Link
12:49 EDTVRXValeant down 10% after Democrats request subpoena
Subscribe for More Information
12:45 EDTVRXHouse Democrats urge Valeant to turn over documents, Bloomberg says
11:28 EDTVRXValeant mentioned cautiously in a Seeking Alpha article
Reference Link
10:20 EDTVRXOptions with increasing implied volatility
Subscribe for More Information
08:24 EDTVRXValeant CEO tells employees bear thesis in media incorrect
Valeant Pharmaceuticals disclosed that it distributed a letter today from its CEO Michael Pearson to employees relating to recent changes in Valeant's stock price. The letter stated in part, "A number of you have asked me and other senior members of our management team about the significant drop in our stock price - especially over the past 5 trading days. While the entire pharmaceutical and biotech sector has been impacted by market volatility and numerous press articles about pharmaceutical pricing, we have been hit particularly hard. After talking with a number of investors and observing the concerns and assertions in the media, I thought it would be helpful to give you my perspective on the two main issues worrying investors: 1) Concern that our business model and strategy is dependent upon large price increases in our U.S. pharmaceutical business, 2) Concern around our exposure to U.S. government drug price reimbursement. I can assure you that this bear thesis is incorrect on both accounts...Turning to the first concern about our business model, the majority of our portfolio will continue to deliver strong volume-based organic growth and is not dependent on price increases...Turning to the second concern about proposed changes to government reimbursed products in the U.S., our exposure to U.S. government reimbursement currently represents approximately 15% of our total revenue. Of this, about one third, or ~5%, represents sales to Medicaid, the Department of Veterans Affairs, the Department of Defense, and other government entities, where the business is at best marginally profitable. Despite this, we continue to offer our products through these programs to ensure these patients continue to have access to needed medications. The remaining 10% of our government exposure is related to Medicare. As I stated above, our overall strategy is to focus on private and cash pay markets and to minimize government reimbursement. I believe our exposure to government reimbursement is lower than any other major pharmaceutical company." Shares of Valeant are down 18% over the past five trading days. They closed Friday down $10.18 to $199.32.
08:08 EDTENDPACETO subsidiary acquires three ANDAs from Endo
Subscribe for More Information
07:52 EDTTEVAIIR Holdings to hold a conference
Subscribe for More Information
07:46 EDTTEVA, VRX, PRGOUBS to hold a field trip
Subscribe for More Information
07:31 EDTMYLMylan launches generic Invega tablets
Subscribe for More Information
07:27 EDTHSP, MYLFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
06:44 EDTENDPEndo to host conference call
Subscribe for More Information
06:39 EDTENDPEndo sees Q3 revenue $720M-$740M, consensus $754.1M
The operations from Par are not expected to have a material impact on Q3 results. Sees Q3 adjusted interest expense of approximately $95M. Sees Q3 adjusted effective tax rate of 2%-4%.
06:39 EDTENDPEndo raises FY15 adjusted EPS to $4.50-$4.60 from $4.40-$4.60, consensus $4.52
Subscribe for More Information
06:37 EDTENDPEndo sees FY16 adjusted EPS $5.85-$6.15, consensus $5.71
Subscribe for More Information
06:37 EDTENDPEndo completes acquisition of Par Pharmaceutical
Subscribe for More Information
05:26 EDTTEVATeva announces approval of Copaxone in Japan
Teva announced the approval by the Japanese Ministry of Health, Labour and Welfare of once-daily COPAXONE 20mg injection for the prevention of relapse of multiple sclerosis . The product will be commercialized in Japan by Takeda Pharmaceutical Company Limited. In Japan, glatiramer acetate was developed as an Unapproved New Drug by Teva Pharmaceutical K.K., a wholly owned subsidiary of Teva, at the request of the MHLW. In March, 2013, Takeda and Teva signed an agreement in which Teva granted Takeda the right to commercialize COPAXONE in Japan. The Japanese approval for COPAXONE is based on the safety and efficacy results of an open-label, 52-week clinical trial conducted by Teva Pharmaceutical K.K. in patients with relapsing-remitting multiple sclerosis in Japan as well as the pivotal trial data sets used for approvals in other countries.
September 27, 2015
16:53 EDTTEVATeva reports Phase 3 data on reslizumab for asthma exacerbations
Teva Pharmaceutical presented results from a post hoc analysis of two pivotal Phase 3 clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations by 75% versus placebo in a subgroup of patients with late onset asthma with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids. Reslizumab is a humanized anti-interleukin-5 monoclonal antibody. Results were pooled from two Phase 3 clinical trials that investigated reslizumab IV 3mg/kg in patients who had at least one asthma exacerbation within the previous year. In the subgroup with late onset asthma, reslizumab showed a 75% reduction in asthma exacerbations and improvement in lung function as measured by forced expiratory volume in one second. In the overall pooled patient population, asthma exacerbations were reduced by 54%, and in the subgroup of subjects diagnosed with asthma at less than 40 years of age, exacerbations were reduced by 42%. Common adverse events in the reslizumab treatment group were comparable to placebo.
1 | 2 | 3 | 4 | 5 | 6 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use